Small cell lung cancer: biological and therapeutic aspects.

[1]  N. Brünner,et al.  Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[2]  M. Spang‐Thomsen,et al.  Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. , 1994, British Journal of Cancer.

[3]  J P Pignon,et al.  Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.

[4]  S. Friend,et al.  The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? , 1993, Journal of the National Cancer Institute.

[5]  K. Kiura,et al.  Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. , 1993, Lung cancer.

[6]  C. Chastang,et al.  A randomized trial of delayed thoracic radiotherapy in complete responder patients with small-cell lung cancer. Petites Cellules Group. , 1993, Chest.

[7]  J. Yokota,et al.  Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. , 1993, Oncogene.

[8]  A. Paccagnella,et al.  Granulocyte‐macrophage colony‐stimulating factor increases dose intensity of chemotherapy in small cell lung cancer: Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics , 1993, Cancer.

[9]  J. Minna,et al.  A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. , 1993, Oncogene.

[10]  A. Bartolucci,et al.  Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Giaccone,et al.  Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Chalmers,et al.  Meta-analysis of radiotherapy for small-cell lung cancer. , 1993, The New England journal of medicine.

[13]  D. Ettinger,et al.  Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Spang‐Thomsen,et al.  Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. , 1993, British Journal of Cancer.

[15]  M. Spang‐Thomsen,et al.  Expression of myc family oncoproteins in small‐cell lung‐cancer cell lines and xenografts , 1993, International journal of cancer.

[16]  F. Baas,et al.  Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. , 1993, Cancer research.

[17]  J. Eder,et al.  Intensive combined modality therapy for limited-stage small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[18]  J. Minna.  The molecular biology of lung cancer pathogenesis. , 1993, Chest.

[19]  H. Hansen,et al.  Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. , 1993, Biochemical pharmacology.

[20]  T. Lynch.  Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. , 1993, Chest.

[21]  Johnson Be,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[22]  G. Lyman,et al.  Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. , 1993, Journal of the National Cancer Institute.

[23]  J. Herndon,et al.  Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. , 1993, Journal of the National Cancer Institute.

[24]  H. Hansen,et al.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. , 1993, British Journal of Cancer.

[25]  D. Payne,et al.  Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[27]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[28]  J P Pignon,et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.

[29]  A. Brugarolas,et al.  Urokinase combination chemotherapy in small cell lung cancer. A phase II study , 1992, Cancer.

[30]  C. Creutz,et al.  Lambert–Eaton syndrome: Antigen–antibody interaction and calcium current inhibition in chromaffin cells , 1992, Muscle & nerve.

[31]  E. Warner,et al.  A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. , 1992, Seminars in oncology.

[32]  P. Sørensen,et al.  Metastatic spinal cord compression secondary to lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J N Weinstein,et al.  Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.

[34]  M. Lishner,et al.  Second primary malignancies following diagnosis of small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Oren.  p53: the ultimate tumor suppressor gene? , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  R. Souhami,et al.  An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer. , 1992, British Journal of Cancer.

[37]  H. Hansen,et al.  Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Aamdal,et al.  Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. , 1992, The American journal of pathology.

[39]  H. Hansen,et al.  Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). , 1992, British Journal of Cancer.

[40]  M. Green,et al.  Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Fukuoka,et al.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Fukuoka,et al.  Detection of large cell component in small cell lung carcinoma by combined cytologic and histologic examinations and its clinical implication , 1992, Cancer.

[43]  E. Vellenga,et al.  Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L V Rubinstein,et al.  Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. , 1992, Cancer research.

[45]  H. Poulsen,et al.  Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. , 1992, Cancer research.

[46]  A. Fraire,et al.  Prognostic significance of histopathologic subtype and stage in small cell lung cancer. , 1992, Human pathology.

[47]  R. Cellerino,et al.  Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. , 1992, European journal of cancer.

[48]  P. Clementsen,et al.  Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. , 1992, European journal of cancer.

[49]  U. Gatzemeier,et al.  Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Smyth,et al.  Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. , 1992, Cancer research.

[51]  Y. Miller,et al.  Urinary levels of bombesin-like peptides in asymptomatic cigarette smokers: a potential risk marker for smoking-related diseases. , 1992, Cancer research.

[52]  K. Alitalo,et al.  Amplification and rearrangement of L-myc in human small-cell lung cancer. , 1992, Mutation research.

[53]  T Takahashi,et al.  Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. , 1992, Cancer research.

[54]  G. Giaccone.  Teniposide alone and in combination chemotherapy in small cell lung cancer. , 1992, Seminars in oncology.

[55]  G. Giaccone,et al.  Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. , 1992, Cancer research.

[56]  R. Ueda,et al.  Three distinct regions involved in 3p deletion in human lung cancer. , 1992, Oncogene.

[57]  F. Abreo,et al.  Radiotherapeutic Palliation of Spinal Epidural Compression in Small‐Cell Lung Cancer , 1992, Southern medical journal.

[58]  S. Hirohashi,et al.  Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. , 1992, Oncogene.

[59]  J. Testa,et al.  Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. , 1992, Cancer research.

[60]  C. Chastang,et al.  Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group. , 1992, The European respiratory journal.

[61]  S. Cole.  The 1991 Merck Frosst Award. Multidrug resistance in small cell lung cancer. , 1992, Canadian journal of physiology and pharmacology.

[62]  M. Kris,et al.  Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Minna,et al.  High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. , 1992, Oncogene.

[64]  E. Smit,et al.  Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. , 1992, Seminars in oncology.

[65]  U. Gatzemeier,et al.  Phase II and III studies with carboplatin in small cell lung cancer. , 1992, Seminars in oncology.

[66]  M. Fukuoka,et al.  Weekly Dose‐Intensive Chemotherapy in Patients with Small‐Cell Lung Cancer: A Pilot Study , 1992, American journal of clinical oncology.

[67]  J. Jassem,et al.  Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group. , 1992, European journal of cancer.

[68]  J. Crawford,et al.  Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  L. Einhorn,et al.  Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer , 1992, Cancer.

[70]  P. Corris,et al.  Alveolar macrophage function before and during treatment with cytotoxic chemotherapy in patients with small cell lung cancer. , 1991, European journal of cancer.

[71]  E. Eisenhauer,et al.  Phase II study of sulofenur (LY 186641) in untreated patients with extensive small cell lung cancer , 1991 .

[72]  M. Kris,et al.  Twice daily thoracic irradiation for limited small cell lung cancer. , 1991, International journal of radiation oncology, biology, physics.

[73]  W. Hong,et al.  Resectability of Small‐Cell Lung Cancer Following Induction Chemotherapy in Patients with Limited Disease (Stage II‐IIIb) , 1991, American journal of clinical oncology.

[74]  M. Brattain,et al.  Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. , 1991, Cancer research.

[75]  R. Ueda,et al.  The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. , 1991, Oncogene.

[76]  R. Stephens,et al.  A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party. , 1991, British Journal of Cancer.

[77]  U Sagman,et al.  Small-cell carcinoma of the lung: derivation of a prognostic staging system. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  N. Murray,et al.  Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[79]  H. Earl,et al.  A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. , 1991, British Journal of Cancer.

[80]  I. Smith,et al.  Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. , 1991, British Journal of Cancer.

[81]  R. Carlson,et al.  Late consolidative radiation therapy in the treatment of limited‐stage small cell lung cancer , 1991, Cancer.

[82]  H. Hansen,et al.  Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  D. Osoba,et al.  Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. Fukuoka,et al.  Redevelopment of Small‐Cell Lung Cancer Nine Years after the Start of Therapy A Case Report and Review of the Literature , 1991, American journal of clinical oncology.

[85]  G. Wampler,et al.  Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  J. Radford,et al.  Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[88]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[89]  S. Mirski,et al.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. , 1991, Cancer research.

[90]  M. Reynaud‐Gaubert,et al.  Phase II study of pirarubicin in untreated metastatic small cell lung carcinoma , 1991 .

[91]  I. Smith,et al.  Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide. , 1991, European journal of cancer.

[92]  A. F. Sagarra,et al.  A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer , 1991, Cancer.

[93]  K. Suemasu,et al.  Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[94]  R. Arriagada,et al.  A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma , 1991, Cancer.

[95]  L. Loeb,et al.  Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.

[96]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[97]  R. Holle,et al.  Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. , 1991, British Journal of Cancer.

[98]  A. Chella,et al.  Surgery Plus Adjuvant Chemotherapy for T1–3N0M0 Small‐Cell Lung Cancer: Rationale for Current Approach , 1991, American journal of clinical oncology.

[99]  J. Yokota,et al.  Chromosomal localization of putative tumor-suppressor genes in several human cancers. , 1991, Environmental health perspectives.

[100]  D. Payne,et al.  The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  O. Haas,et al.  MDR1 gene expression and treatment outcome in acute myeloid leukemia. , 1991, Journal of the National Cancer Institute.

[102]  H. Herweijer,et al.  Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.

[103]  R. Stahel.  Diagnosis, staging, and prognostic factors of small cell lung cancer. , 1991, Current opinion in oncology.

[104]  H. Flechtner,et al.  Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  G. Anderson,et al.  Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. , 1991, Thorax.

[106]  J. Crowley,et al.  Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  A. Coldman,et al.  Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  R. Ginsberg,et al.  Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. , 1991, The Journal of thoracic and cardiovascular surgery.

[109]  K. Eguchi,et al.  A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer. , 1991, Japanese journal of clinical oncology.

[110]  H. Earl,et al.  Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  V. Devita.  The influence of information on drug resistance on protocol design. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  R. Ginsberg,et al.  Is there ever a role for salvage operations in limited small-cell lung cancer? , 1991, The Journal of thoracic and cardiovascular surgery.

[113]  F. Hirsch,et al.  Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. , 1991, British Journal of Cancer.

[114]  J. J. Perry,et al.  Small cell lung cancer: staging with MR imaging. , 1990, Radiology.

[115]  H. Hansen,et al.  Second-line chemotherapy in small cell lung cancer. , 1990, Cancer treatment reviews.

[116]  E. Frenkel,et al.  The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  A. Turrisi,et al.  Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. , 1990, International journal of radiation oncology, biology, physics.

[118]  M. Sehested,et al.  A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells. , 1990, Biochimica et biophysica acta.

[119]  R. Leonard,et al.  Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer. , 1990, Cancer research.

[120]  J. Crowley,et al.  Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  P. Yaciuk,et al.  TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains , 1990, Cell.

[122]  S. Bicknell,et al.  High dose epirubicin chemotherapy in untreated poorer prognosis small cell lung cancer. , 1990, Respiratory medicine.

[123]  S. Kaye,et al.  Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? , 1990, British Journal of Cancer.

[124]  J. Peto,et al.  An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. , 1990, British Journal of Cancer.

[125]  J. Armstrong.  Long-term outcome of small cell lung cancer. , 1990, Cancer treatment reviews.

[126]  D. Ettinger,et al.  The clinical significance of variant-morphology small-cell carcinoma of the lung. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  W. Boogerd,et al.  Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis , 1990, Cancer.

[128]  D. Ettinger,et al.  A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  W. Kisiel,et al.  Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung , 1990, Cancer.

[130]  S. de Jong,et al.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. , 1990, Cancer research.

[131]  K. Østerlind.  Alternating or sequential chemotherapy in small cell lung cancer , 1989 .

[132]  T. Schwartz,et al.  Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  H. Hansen,et al.  In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). , 1989, British Journal of Cancer.

[134]  M. Cullen.  The design of phase II trials , 1989 .

[135]  D. Ettinger,et al.  Management of CNS metastases in small cell lung cancer: a consensus report , 1989 .

[136]  L. Teodori,et al.  DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Prognostic implications. , 1989, Chest.

[137]  P. Woll,et al.  Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. , 1989, Biochemical and biophysical research communications.

[138]  M. Oshimura,et al.  Concordant deletions of chromosome 3p and loss of heterozygosity for chromosomes 13 and 17 in small cell lung carcinoma. , 1989, Cancer research.

[139]  P. Rabbitts,et al.  Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. , 1989, British Journal of Cancer.

[140]  V. Gebski,et al.  Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. , 1989, British Journal of Cancer.

[141]  M. Ro̸rth,et al.  Growth factors and growth factor receptors in human malignancies, with special reference to human lung cancer: a review , 1989 .

[142]  I. Pastan,et al.  MDR1 gene expression in lung cancer. , 1989, Journal of the National Cancer Institute.

[143]  B. Malfroy,et al.  Effects of bombesin on human small cell lung cancer cells: Evidence for a subset of bombesin non‐responsive cell lines , 1989, Journal of cellular biochemistry.

[144]  K. Propert,et al.  A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  L. de Leij,et al.  Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. , 1989, Cancer research.

[146]  H. Earl,et al.  Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. , 1989, British Journal of Cancer.

[147]  M. Weil,et al.  Mechanism of blood flow generated by precordial compression during CPR. I. Studies on closed chest precordial compression. , 1989, Chest.

[148]  J. Hainsworth,et al.  Combined small-cell and non-small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  P. Fayers,et al.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. , 1989, British Journal of Cancer.

[150]  M. Partridge,et al.  Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. , 1989, British Journal of Cancer.

[151]  H. Hansen,et al.  The prognostic influence of serum neuron specific enolase in small cell lung cancer. , 1988, British Journal of Cancer.

[152]  D. Suttle,et al.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. , 1988, Biochemistry.

[153]  A. Twijnstra,et al.  A lethal neurotoxic reaction after intraventricular methotrexate administration , 1988, Cancer.

[154]  Y. Cheng,et al.  Combined modalities of resistance in etoposide-resistant human KB cell lines. , 1988, Cancer research.

[155]  M. Socinski,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.

[156]  R. Steele,et al.  Histopathologic classification of small cell lung cancer changing concepts and terminology , 1988, Cancer.

[157]  D. Ihde,et al.  Therapy of small cell lung cancer: a perspective on two decades of clinical research. , 1988, Seminars in oncology.

[158]  J. Carmichael,et al.  Results of therapeutic cranial irradiation in small cell lung cancer. , 1988, International journal of radiation oncology, biology, physics.

[159]  P. Corris,et al.  The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. , 1988, European journal of cancer & clinical oncology.

[160]  D. Crowther,et al.  Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. , 1987, British Journal of Cancer.

[161]  M. Sehested,et al.  Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. , 1987, British Journal of Cancer.

[162]  N. Murray.  The importance of dose and dose intensity in lung cancer chemotherapy. , 1987, Seminars in oncology.

[163]  J. Machiels,et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  W. Kisiel,et al.  Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung , 1987, Cancer.

[165]  G. Giaccone,et al.  Reinduction chemotherapy in small cell lung cancer. , 1987, European journal of cancer & clinical oncology.

[166]  J. Herman,et al.  Neurologic disorders in patients with small cell lung cancer , 1987, Cancer.

[167]  J. Gasson,et al.  Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. , 1987, Blood.

[168]  R. Feld,et al.  Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. , 1987, Cancer treatment reports.

[169]  R. Buchanan,et al.  Surgery after initial chemotherapy for localized small-cell carcinoma of the lung. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  R. Hitchins,et al.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  D. Osoba,et al.  Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. , 1987, Annals of internal medicine.

[172]  P. Postmus,et al.  Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. , 1987, European journal of cancer & clinical oncology.

[173]  D. Osoba,et al.  Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  F. Balkwill,et al.  INTERFERONS IN CANCER THERAPY: A REAPPRAISAL , 1987, The Lancet.

[175]  L. Einhorn,et al.  Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. , 1987, Chest.

[176]  P. Andersen,et al.  Determinants of complete remission induction and maintenance in chemotherapy with or without irradiation of small cell lung cancer. , 1987, Cancer research.

[177]  D. Ettinger,et al.  The role of surgery in the management of selected patients with small-cell carcinoma of the lung. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  C. Mountain.  Staging of lung cancer: The new international system , 1987 .

[179]  R. Makuch,et al.  Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. , 1987, Annals of internal medicine.

[180]  J. Ware,et al.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. , 1987, The New England journal of medicine.

[181]  F. Hirsch,et al.  The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  J. Crowley,et al.  Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  R. Holle,et al.  Alternating versus sequential chemotherapy in small cell lung cancer. A randomized german multicenter trial , 1987, Cancer.

[184]  D. Carney.  Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide , 1987, Regulatory Peptides.

[185]  R. Abrams,et al.  Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  P. Andersen,et al.  Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. , 1986, Cancer research.

[187]  P. Bunn,et al.  Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  G. Bodey,et al.  Combination chemotherapy with vindesine and cisplatin for refractory small cell bronchogenic carcinoma. , 1986, Cancer treatment reports.

[189]  F. Greco,et al.  Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.

[190]  J. Cox,et al.  Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). , 1986, International journal of radiation oncology, biology, physics.

[191]  F. Hirsch,et al.  Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients , 1986, Cancer.

[192]  R. Souhami,et al.  Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[193]  R. J. Cersosimo,et al.  Disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with small cell lung cancer. , 1985, Cancer treatment reports.

[194]  D. Osoba,et al.  VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  F. Hirsch,et al.  Serum Lactate Dehydrogenase and Bone Marrow Metastases in Small-Cell Carcinoma of the Lung , 1985 .

[196]  R. Wittes,et al.  Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer. , 1985, American Journal of Medicine.

[197]  R. Arriagada,et al.  Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease. , 1985, International journal of radiation oncology, biology, physics.

[198]  N. Brünner,et al.  Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. , 1985, European journal of cancer & clinical oncology.

[199]  R. Souhami,et al.  High-dose cyclophosphamide in small-cell carcinoma of the lung. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  J. Bergh,et al.  Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. , 1985, American journal of clinical pathology.

[201]  R. Souhami,et al.  Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. , 1985, Cancer research.

[202]  P. Rubin,et al.  Prophylactic versus no brain irradiation in regional small cell lung carcinoma , 1985, American journal of clinical oncology.

[203]  G. Bepler,et al.  Establishment and identification of small cell lung cancer cell lines having classic and variant features. , 1985, Cancer research.

[204]  M. Mckneally,et al.  Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. , 1985, Cancer treatment reports.

[205]  Doll Dc.  Serum lactate dehydrogenase and bone marrow involvement in small-cell carcinoma of the lung. , 1985 .

[206]  D. Johnson,et al.  Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. , 1985, Cancer treatment reports.

[207]  A. Pedersen,et al.  Frequency, diagnosis, and prognosis of spinal cord compression in small cell bronchogenic carcinoma. A review of 817 consecutive patients , 1985, Cancer.

[208]  W. Haseltine,et al.  Alkylating agent resistance: in vitro studies with human cell lines. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[209]  J. Mann,et al.  Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. , 1985, Cancer treatment reports.

[210]  J. Sculier,et al.  Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  D. Gandara,et al.  Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  H. Cohen,et al.  Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  R. Stahel,et al.  Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. , 1984, European journal of cancer & clinical oncology.

[214]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[215]  E. Noordijk,et al.  Combined modality treatment of short duration in small cell lung cancer. , 1984, European journal of cancer & clinical oncology.

[216]  R. Souhami,et al.  Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. , 1984, British medical journal.

[217]  D. Osoba,et al.  VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer , 1984, Cancer.

[218]  J. Herman,et al.  Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[219]  F. Hirsch,et al.  Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. , 1983, Cancer research.

[220]  F. Appelbaum,et al.  Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. , 1983, Cancer treatment reports.

[221]  H. Skipper,et al.  Establishment of cross-resistance profiles for new agents. , 1983, Cancer treatment reports.

[222]  R. Stevenson,et al.  Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna. , 1983, Cancer treatment reviews.

[223]  D. V. Van Echo,et al.  Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. , 1983, Cancer treatment reports.

[224]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[225]  T. Shields,et al.  Surgical resection in the management of small cell carcinoma of the lung. , 1982, The Journal of thoracic and cardiovascular surgery.

[226]  F. Greco,et al.  Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. , 1982, The American journal of medicine.

[227]  J. Klastersky,et al.  Cisplatin, adriamycin, and etoposide (cav) for remission induction of small‐cell bronchogenic carcinoma. Evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone‐marrow rescue , 1982, Cancer.

[228]  E P Frenkel,et al.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[229]  L. Jenkyn,et al.  Prophylactic cranial irradiation in small cell carcinoma of the lung. , 1982, Rhode Island medical journal.

[230]  J. Minna,et al.  SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER , 1982, The Lancet.

[231]  Goldie Jh,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982 .

[232]  D. V. Van Echo,et al.  Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. , 1982, Cancer treatment reports.

[233]  R. Sonntag,et al.  Chemotherapy of small cell carcinoma of the lung: comparison of a cyclic alternative combination with simultaneous combinations of four and seven agents. , 1981, European journal of cancer & clinical oncology.

[234]  Maurer Lh,et al.  Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study. , 1981 .

[235]  S. Baylin,et al.  Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung—assessment of clinical implications in patients on combination chemotherapy , 1981, Cancer.

[236]  R. Makuch,et al.  Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. , 1981, Cancer treatment reports.

[237]  W. Henderson,et al.  Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. , 1981, JAMA.

[238]  R. Young,et al.  Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. , 1980, Journal of neurosurgery.

[239]  F. Hirsch,et al.  Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. , 1980, Cancer research.

[240]  D. Shore,et al.  Survival after resection of small cell carcinoma of the bronchus. , 1980, Thorax.

[241]  M. Tattersall,et al.  A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. , 1980, International journal of radiation oncology, biology, physics.

[242]  R. Creech,et al.  "The state of the art" toward defining the role of radiation therapy in the management of small cell bronchogenic carcinoma. , 1980, International journal of radiation oncology, biology, physics.

[243]  F. Hirsch,et al.  Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy , 1980, Cancer.

[244]  R. Comis,et al.  Abnormalities in water homeostasis in small cell anaplastic lung cancer , 1980, Cancer.

[245]  J. Minna,et al.  Long-term survivors with small cell carcinoma of the lung. , 1980, European journal of cancer.

[246]  J. M. Christensen,et al.  Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes , 1980, Cancer.

[247]  J. Minna,et al.  CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival , 1979, Cancer.

[248]  J. Minna,et al.  Response to thoracic radiotherapy in patients with small cell carcinoma of the lung after failure of combination chemotherapy. , 1979, Radiology.

[249]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[250]  D. Ettinger,et al.  Intensive induction therapy for small cell carcinoma of the lung. , 1979, Cancer treatment reports.

[251]  R. Makuch,et al.  Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. , 1979, Cancer treatment reports.

[252]  R. Kane,et al.  Low dose elective brain irradiation in small cell carcinoma of the lung. , 1978, International journal of radiation oncology, biology, physics.

[253]  F. Hirsch,et al.  Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. , 1978, Annals of internal medicine.

[254]  Z. Petrovich,et al.  Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Preliminary report of a cooperative trial , 1977, Cancer.

[255]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[256]  J. Posner,et al.  Treatment of meningeal neoplasms. , 1977, Cancer treatment reports.

[257]  Z. Petrovich,et al.  Clinical report on the treatment of locally advanced lung cancer , 1977 .

[258]  C. Spurr,et al.  Prophylactic cranial irradiation in small cell carcinoma of the lung: A Randomized Study , 1977 .

[259]  J. Minna,et al.  Combination chemotherapy with vincristine, adriamycin, and procarbazine in previously treated patients with small cell carcinoma. , 1977, Cancer treatment reports.

[260]  J. Minna,et al.  Intensive chemotherapy of small cell bronchogenic carcinoma. , 1977, Cancer treatment reports.

[261]  Posner Jb.  Management of central nervous system metastases. , 1977, Seminars in oncology.

[262]  H. Hansen,et al.  Combination chemotherapy of advanced lung cancer. A randomized trial , 1976, Cancer.

[263]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[264]  D. Kuhl,et al.  The effect of steroids on the extravascular distribution of radiographic contrast material and technetium pertechnetate in brain tumors as determined by computed tomography. , 1976, Radiology.

[265]  H. Wisniewski,et al.  IMMUNOSUPPRESSION BY LINOLEIC ACID , 1975, The Lancet.

[266]  W. Fox,et al.  Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. , 1973, Lancet.

[267]  D. White,et al.  Lung cancer: Clinical trial of radiotherapy alone vs. Radiotherapy plus cyclophosphamide , 1972, Cancer.

[268]  A. Pack,et al.  Intensive-coronary-care units. , 1970, Lancet.

[269]  A. Miller,et al.  Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. , 1969, Lancet.

[270]  V. C. Thompson,et al.  Results of resection for oat-cell carcinoma of the lung. , 1968, Lancet.

[271]  N. Kaplan,et al.  LACTIC DEHYDROGENASE IN HUMAN NEOPLASTIC TISSUES. , 1964, Cancer research.

[272]  M. Sehested,et al.  Relationship of VP-16 to the Classical Multidrug Resistance Phenotype1 , 2006 .

[273]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[274]  P. Sørensen,et al.  Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. , 1994, European journal of cancer.

[275]  G. Prévost,et al.  Therapeutic use and perspectives of synthetic peptides in oncology. , 1993, Acta oncologica.

[276]  J. von Pawel,et al.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. , 1993, European journal of cancer.

[277]  E. Smit,et al.  Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. , 1993, European journal of cancer.

[278]  T. Moody,et al.  Growth factor and peptide receptors in small cell lung cancer. , 1993, Life sciences.

[279]  P. Kristjansen,et al.  The role of prophylactic cranial irradiation in the management of small cell lung cancer. , 1993, Cancer treatment reviews.

[280]  J. Oates,et al.  Somatostatin analogue phase I trials in neuroendocrine neoplasms. , 1993, Acta oncologica.

[281]  L. Crinò,et al.  High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. , 1993, European journal of cancer.

[282]  J. Mulshine,et al.  Initiators and promoters of lung cancer. , 1993, Chest.

[283]  P. Bunn,et al.  Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. , 1992, Cancer research.

[284]  G. Giaccone,et al.  Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. , 1992, European Journal of Cancer.

[285]  F. Shepherd,et al.  Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[286]  E. Alba,et al.  Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[287]  N. Saijo.  Combined modality therapy for small cell lung cancer. , 1992, Oncology.

[288]  J. von Pawel,et al.  Carboplatin/etoposide/vincristine therapy in small cell lung cancer. , 1992, Oncology.

[289]  M. Fukuoka,et al.  CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. , 1992, Oncology.

[290]  K. Cantell,et al.  Natural interferon alfa as maintenance therapy for small cell lung cancer. , 1992, European journal of cancer.

[291]  P. Postmus,et al.  Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. , 1992, European journal of cancer.

[292]  J. Lankelma,et al.  Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. , 1992, Cancer research.

[293]  M. Dimopoulos,et al.  Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer , 1992, Cancer.

[294]  G. Wampler,et al.  A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma. , 1992, Cancer investigation.

[295]  J. Bishop.  Carboplatin/etoposide in small cell lung cancer. , 1992, Oncology.

[296]  P. Willcox,et al.  Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. , 1991, European journal of cancer.

[297]  A. Lange,et al.  Aggressive chemotherapy with autologous bone marrow transplantation in small cell lung carcinoma. , 1991, Archivum immunologiae et therapiae experimentalis.

[298]  N. Thatcher,et al.  Recombinant human GM-CSF in small cell lung cancer: a phase I/II study. , 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[299]  F. Hirsch,et al.  Original article: Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens , 1991 .

[300]  H. Hansen,et al.  Chemotherapy of small cell lung cancer. , 1991, European journal of cancer.

[301]  G. Giaccone,et al.  Pilot study of teniposide in combination chemotherapy for small cell lung cancer. , 1991, European journal of cancer.

[302]  P. Borst.  Genetic mechanisms of drug resistance. A review. , 1991, Acta oncologica.

[303]  A. Gazdar,et al.  Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. , 1990, European journal of cancer.

[304]  J. Blasko,et al.  Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[306]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[307]  A. Niiranen,et al.  Treatment of small cell lung cancer. Two-drug versus four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation. , 1989, Acta oncologica.

[308]  A. Pedersen.  Diagnostic Procedures in the Detection of CNS Metastases from Small Cell Lung Cancer , 1986 .

[309]  C. Cordon-Cardo,et al.  Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. , 1986, The American journal of medicine.

[310]  H. Hansen,et al.  Lung Cancer: Basic and Clinical Aspects , 1986, Cancer Treatment and Research.

[311]  A. Zander,et al.  High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[312]  W. Hryniuk,et al.  Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[313]  M. Zucchetti,et al.  Pharmacokinetics of VP16 in patients with impaired renal function , 1985 .

[314]  D. Osoba,et al.  Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[315]  B. Milleron,et al.  Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. , 1985, Chest.

[316]  P. Mehta.  Potential role of platelets in the pathogenesis of tumor metastasis , 1984 .

[317]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[318]  A. Gazdar,et al.  Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. , 1982, Stem cells.

[319]  J. Ingle,et al.  A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer. , 1981, Cancer clinical trials.

[320]  J. Marks,et al.  Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung , 1981, Cancer.

[321]  T. Pajak,et al.  A randomized combined modality trial in small cell carcinoma of the lung comparison of combination chemotherapy‐radiation therapy versus cyclophosphamide‐radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation , 1980, Cancer.

[322]  W. Bleyer,et al.  Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. , 1979, Medical and pediatric oncology.

[323]  T. Deeley.  A clinical trial to compare two different tumour dose levels in the treatment of advanced carcinoma of the bronchus. , 1966, Clinical Radiology.